{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46","value":"1212.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"AUC0-24 of Crizotinib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who were enrolled in enriched RP2D cohort received single dose of Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally with food on Day -7.","id":"OG000","title":"RP2D Cohort: Crizotinib 250 mg With Food"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The food effect analysis set included all participants treated (including Day -7 dose) and in the RP2D cohort who had received a dose of crizotinib under fed conditions and for which at least 1 PK parameter of interest (Cmax or AUC) was available. Here, \"Overall number of participants analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"pre-dose, 1, 2, 4, 6, 8, 9, and 24 hours post-dose on Day -7","title":"RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food","type":"PRIMARY","unitOfMeasure":"nanogram*hour per milliliter"}